Lineages with #N440K are NOT the dominant ones in the second wave of #Covid19inIndia. While N440K was a indeed mutation of concern in South India during and after the first wave, current data shows that it is essentially replaced by new VoCs such as #B1617 and #B117
When comparing the data from MH, in MH we can see that the increase in B.1.617 is seen in Feb rather than Mar 2021, and again we observe a reduction in proportion of lineages with N440K.
This coincides well with the second waves seen in the respective states. In MH, the second wave started almost a month and half earlier compared to the 4 southern states, along with the explosion of B.1.617 at the expense of lineages with the mutation N440K.
In KL, though not much data is available on GISAID, we can see from genescov2.genomes.in that B.1.1.7 is increasing at present, whereas N440K is present in <20% of the genomes
Also, it is important to remember that just because a variant behaves a certain way in cell cultures (with no competition, and in controlled settings), it does not mean it will behave the same way in humans, or in a complicated pandemic scenario.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
So much misinformation and confusion about the circulating #SARSCoV2 variants in India. Leaving aside that the names are scientifically inaccurate, #B1618 ("Bengal variant") is NOT the #tripleMutant. I will try to summarize the basics in this thread.
(1/n)
B.1.617: characterized by more than 15 mutations, it got dubbed the "double mutant" because of two spike mutations, L452R and E484Q, which were mutations of concern because of their immune escape properties, and possible high infectivity.
What's more, there are several sequences of B.1.617 which don't have the E484Q mutation, now sampled in India and elsewhere, which means it's not even the OG "double mutant" anymore.
I’ve never done one of these before, but I’m gonna make a thread of tweets explaining the key findings, and more importantly what our paper doesn’t show. 1/n
First and foremost, there is no conclusive evidence at present that any clade of SARS-CoV-2 is associated with increased mortality or severity of the disease. 2/n